CNSP Key Statistics, Chart & Performance
The current stock price of CNSP is 4.51 USD. In the past month the price decreased by -24.07%. In the past year, price decreased by -91.98%.
CNSP Technical Analysis
CNSP Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CNSP. While CNSP seems to be doing ok healthwise, there are quite some concerns on its profitability.
CNSP Financial Highlights
Over the last trailing twelve months CNSP reported a non-GAAP Earnings per Share(EPS) of -130.83. The EPS increased by 99.73% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -110.13% | ||
| ROE | -131.9% | ||
| Debt/Equity | 0 |
CNSP Forecast & Estimates
8 analysts have analysed CNSP and the average price target is 53.04 USD. This implies a price increase of 1076.05% is expected in the next year compared to the current price of 4.51.
CNSP Ownership
CNSP Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 31.53 | 965.082B | ||
| JNJ | JOHNSON & JOHNSON | 20.76 | 572.907B | ||
| MRK | MERCK & CO. INC. | 22.54 | 297.222B | ||
| PFE | PFIZER INC | 9.06 | 150.614B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 10.19 | 121.168B | ||
| ZTS | ZOETIS INC | 18.6 | 55.849B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.61 | 25.456B | ||
| VTRS | VIATRIS INC | 5.78 | 16.516B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.9 | 12.079B | ||
| AXSM | AXSOME THERAPEUTICS INC | 223.48 | 9.116B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CNSP
Company Profile
CNS Pharmaceuticals, Inc. is a preclinical stage pharmaceutical company, which engages in the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. The company is headquartered in Houston, Texas and currently employs 4 full-time employees. The company went IPO on 2019-11-08. The firm's drug candidate, Berubicin, is the first anthracycline to appear to cross the blood-brain barrier. Berubicin is the subject of the Company's late-stage, fully-enrolled, global clinical trial for the treatment of glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. The firm's drug candidate, TPI 287, is an abeotaxane which stabilizes microtubules and inhibits cell division, causing apoptosis and cell death. TPI 287 has shown the potential to cross the blood-brain barrier and treat central nervous system (CNS) tumors.
Company Info
CNS PHARMACEUTICALS INC
2100 West Loop S Ste 900
Houston TEXAS 77027 US
CEO: John Climaco
Employees: 4
Phone: 18009469185
CNS PHARMACEUTICALS INC / CNSP FAQ
What does CNSP do?
CNS Pharmaceuticals, Inc. is a preclinical stage pharmaceutical company, which engages in the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. The company is headquartered in Houston, Texas and currently employs 4 full-time employees. The company went IPO on 2019-11-08. The firm's drug candidate, Berubicin, is the first anthracycline to appear to cross the blood-brain barrier. Berubicin is the subject of the Company's late-stage, fully-enrolled, global clinical trial for the treatment of glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. The firm's drug candidate, TPI 287, is an abeotaxane which stabilizes microtubules and inhibits cell division, causing apoptosis and cell death. TPI 287 has shown the potential to cross the blood-brain barrier and treat central nervous system (CNS) tumors.
What is the current price of CNSP stock?
The current stock price of CNSP is 4.51 USD. The price decreased by -0.88% in the last trading session.
Does CNS PHARMACEUTICALS INC pay dividends?
CNSP does not pay a dividend.
How is the ChartMill rating for CNS PHARMACEUTICALS INC?
CNSP has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the PE ratio for CNSP stock?
CNS PHARMACEUTICALS INC (CNSP) does not have a PE ratio as the earnings reported over the last twelve months were negative (-130.83).
Can you provide the market cap for CNS PHARMACEUTICALS INC?
CNS PHARMACEUTICALS INC (CNSP) has a market capitalization of 2.80M USD. This makes CNSP a Nano Cap stock.
Can you provide the upcoming earnings date for CNS PHARMACEUTICALS INC?
CNS PHARMACEUTICALS INC (CNSP) will report earnings on 2026-03-30, after the market close.